NCT03709888View on ClinicalTrials.gov

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

July 9, 2016

Primary Completion Date

April 29, 2021

Study Completion Date

April 29, 2021

Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
DRUG

Memantine XR-pregabalin combination therapy

Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.

Trial Locations (1)

90404

John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica

All Listed Sponsors
lead

Saint John's Cancer Institute

OTHER

NCT03709888 - Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy | Biotech Hunter | Biotech Hunter